These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20658437)

  • 21. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy.
    Ha H; Hwang IA; Park JH; Lee HB
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S42-5. PubMed ID: 18845352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
    Inagi R; Nangaku M; Miyata T
    Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U; Chen XM; Pollock CA
    Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.
    Hagiwara S; Makita Y; Gu L; Tanimoto M; Zhang M; Nakamura S; Kaneko S; Itoh T; Gohda T; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2006 Mar; 21(3):605-15. PubMed ID: 16282336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes.
    Fujii H; Kono K; Nakai K; Goto S; Komaba H; Hamada Y; Shinohara M; Kitazawa R; Kitazawa S; Fukagawa M
    Am J Nephrol; 2010; 31(4):342-52. PubMed ID: 20224273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smoking: a factor promoting onset and progression of diabetic nephropathy.
    Ritz E; Ogata H; Orth SR
    Diabetes Metab; 2000 Jul; 26 Suppl 4():54-63. PubMed ID: 10922974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sirt1 in diabetic nephropathy].
    Kume S; Koya D; Maegawa H
    Nihon Jinzo Gakkai Shi; 2011; 53(7):1010-5. PubMed ID: 22073865
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of the potassium channel KCa3.1 in diabetic nephropathy.
    Huang C; Pollock CA; Chen XM
    Clin Sci (Lond); 2014 Oct; 127(7):423-33. PubMed ID: 24963668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drosophila Renal Organ as a Model for Identification of Targets and Screening of Potential Therapeutic Agents for Diabetic Nephropathy.
    Rani L; Gautam NK
    Curr Drug Targets; 2018; 19(16):1980-1990. PubMed ID: 30088447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of microRNA in diabetic nephropathy: isolation, quantification and biological function.
    Kantharidis P; Hagiwara S; Brennan E; McClelland AD
    Nephrology (Carlton); 2015 Mar; 20(3):132-9. PubMed ID: 25487691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy.
    Fechete R; Heinzel A; Perco P; Mönks K; Söllner J; Stelzer G; Eder S; Lancet D; Oberbauer R; Mayer G; Mayer B
    Proteomics Clin Appl; 2011 Jun; 5(5-6):354-66. PubMed ID: 21491608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic agents in diabetic nephropathy.
    Kim Y; Park CW
    Korean J Intern Med; 2017 Jan; 32(1):11-25. PubMed ID: 28049280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive diabetic nephropathy in the Ren-2 rat.
    Kelly DJ; Wilkinson-Berka JL; Gilbert RE
    Am J Physiol Renal Physiol; 2007 May; 292(5):F1662; author reply F1663. PubMed ID: 17475900
    [No Abstract]   [Full Text] [Related]  

  • 35. Diabetic nephropathy: causes and managements.
    Tripathi YB; Yadav D
    Recent Pat Endocr Metab Immune Drug Discov; 2013 Jan; 7(1):57-64. PubMed ID: 23227864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial Dysfunction in the Diabetic Kidney.
    Sharma K
    Adv Exp Med Biol; 2017; 982():553-562. PubMed ID: 28551806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of triglyceride-rich lipoproteins in diabetic nephropathy.
    Rutledge JC; Ng KF; Aung HH; Wilson DW
    Nat Rev Nephrol; 2010 Jun; 6(6):361-70. PubMed ID: 20440276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic nephropathy: New insights into established therapeutic paradigms and novel molecular targets.
    Sharma D; Bhattacharya P; Kalia K; Tiwari V
    Diabetes Res Clin Pract; 2017 Jun; 128():91-108. PubMed ID: 28453961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of pro-angiogenic factors and angiogenesis inhibitors in diabetic nephropathy].
    Maeshima Y; Makino H
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():396-400. PubMed ID: 21667492
    [No Abstract]   [Full Text] [Related]  

  • 40. [Microinflammation in diabetic nephropathy].
    Ogawa D; Shikata K
    Nihon Jinzo Gakkai Shi; 2011; 53(7):1021-6. PubMed ID: 22073867
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.